Publication:
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

Simple item page
dc.contributor.authorKÖSTEK, OSMAN
dc.contributor.authorsEsin, Ece; Oksuzoglu, B.; Bilici, A.; Cicin, I.; Kostek, O.; Kaplan, M. A.; Aksoy, S.; Aktas, B. Y.; Ozdemir, O.; Alacacioglu, A.; Cabuk, D.; Sumbul, A. T.; Sakin, A.; Paydas, S.; Yetisir, E.; Er, O.; Korkmaz, T.; Yildirim, N.; Sakalar, T.; Demir, H.; Artac, M.; Karaagac, M.; Harputluoglu, H.; Bilen, E.; Erdur, E.; Degirmencioglu, S.; Aliyev, A.; Cil, T.; Olgun, P.; Basaran, G.; Gumusay, O.; Demir, A.; Tanrikulu, E.; Yumuk, P. F.; Imamoglu, Inanc; Oyan, B.; Cetin, B.; Haksoyler, V.; Karadurmus, N.; Erturk, I.; Evrensel, T.; Yilmaz, H.; Beypinar, I.; Kocer, M.; Pilanci, K. N.; Seker, M.; Urun, Y.; Yildirim, N.; Eren, T.; Demirci, U.
dc.date.accessioned2022-03-12T22:39:38Z
dc.date.available2022-03-12T22:39:38Z
dc.date.issued2019
dc.description.abstractPurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
dc.identifier.doi10.1007/s00280-018-3712-7
dc.identifier.eissn1432-0843
dc.identifier.issn0344-5704
dc.identifier.pubmed30377778
dc.identifier.urihttps://hdl.handle.net/11424/235854
dc.identifier.wosWOS:000458407200014
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofCANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPertuzumab
dc.subjectTrastuzumab
dc.subjectAntiHER2
dc.subjectVisceral metastasis
dc.subjectBrain metastasis
dc.subjectCLINICAL-PRACTICE
dc.subjectOLDER PATIENTS
dc.subjectTRIAL
dc.subjectDOCETAXEL
dc.subjectSURVIVAL
dc.subjectPLUS
dc.subjectCHEMOTHERAPY
dc.subjectPACLITAXEL
dc.subjectTHERAPY
dc.titlePertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
dc.typearticle
dspace.entity.typePublication
local.avesis.id92f96744-0d20-4a05-888a-76825de9c3ce
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages13
local.journal.quartileQ2
oaire.citation.endPage143
oaire.citation.issue1
oaire.citation.startPage131
oaire.citation.titleCANCER CHEMOTHERAPY AND PHARMACOLOGY
oaire.citation.volume83
relation.isAuthorOfPublication45c34df1-af1e-4065-bd94-a363edfac03a
relation.isAuthorOfPublication.latestForDiscovery45c34df1-af1e-4065-bd94-a363edfac03a

Files

Collections

Research Outputs